“Still, the accelerated approval came as a surprise to many, given that Elevidys had failed the primary outcome in a Phase I study, unable to significantly improve patients’ functional performance versus placebo.”
What are you talking about Akki ”it showed improvements on many other levels” can’t wait What improvements on what levels? you dig deep to cloud investor confidence yet your sentiment is BUY lol..
PER Price at posting:
8.3¢ Sentiment: Buy Disclosure: Held
